What is the recommended tapering schedule for oxycodone (oxycondone hydrochloride) 30mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Oxycodone 30mg Tapering Protocol

For tapering oxycodone 30mg, a decrease of 10% of the original dose per week is recommended as a reasonable starting point, with individualization based on patient factors and withdrawal symptoms. 1

General Tapering Approach

  • Begin with a 10% reduction of the original dose per week (3mg reduction per week for 30mg oxycodone) 1
  • For patients who have been on opioids for longer durations (years), slower tapers of 10% per month may be better tolerated 1
  • The FDA recommends tapering by 25% to 50% every 2 to 4 days for patients who no longer require therapy 2

Step-by-Step Tapering Schedule for Oxycodone 30mg

Standard Approach (10% weekly reduction):

  • Week 1: Reduce to 27mg daily 1
  • Week 2: Reduce to 24mg daily 1
  • Week 3: Reduce to 21mg daily 1
  • Week 4: Reduce to 18mg daily 1
  • Week 5: Reduce to 15mg daily 1
  • Week 6: Reduce to 12mg daily 1
  • Week 7: Reduce to 9mg daily 1
  • Week 8: Reduce to 6mg daily 1
  • Week 9: Reduce to 3mg daily 1
  • Week 10: Discontinue 1

Alternative Approach (for patients requiring faster tapering):

  • Reduce by 20-50% per week until reaching the smallest available dose unit 1
  • Once the smallest available dose is reached (typically 5mg for oxycodone), increase the interval between doses 1
  • Opioids may be stopped when taken less frequently than once a day 1

Managing Withdrawal Symptoms

  • Monitor for withdrawal symptoms including drug craving, anxiety, insomnia, abdominal pain, vomiting, diarrhea, diaphoresis, mydriasis, tremor, and tachycardia 1
  • Consider α2-adrenergic agonists (clonidine, lofexidine, guanfacine, tizanidine) to reduce sympathetic activity and withdrawal symptoms 1
  • Use symptomatic treatments such as NSAIDs or acetaminophen for muscle aches and pain 1

Special Considerations

  • Tapers may need to be paused and restarted when the patient is ready 1
  • Tapers often need to be slowed once patients reach low dosages 1
  • Consider a taper successful as long as the patient is making progress 1
  • More rapid tapers might be needed for patient safety in circumstances such as overdose 1
  • Avoid ultrarapid detoxification under anesthesia as it is associated with substantial risks, including death 1

Common Pitfalls to Avoid

  • Abrupt discontinuation in physically dependent patients can lead to severe withdrawal symptoms 2
  • If withdrawal symptoms become severe, return to the previous dose level and taper more slowly 2
  • Patients who are not taking opioids (including those diverting all obtained opioids) do not require tapers 1
  • Discuss with patients the increased risk for overdose if they return abruptly to a previously prescribed higher dose 1

Monitoring During Tapering

  • Collaborate with mental health providers and specialists as needed to optimize nonopioid pain management and provide psychosocial support 1
  • Consider offering naloxone for overdose prevention in high-risk patients 1
  • If a patient exhibits signs of opioid use disorder, arrange for appropriate treatment 1

The Mayo Clinic approach uses a gradual, structured taper over 3 weeks with completion rates above 90%, though this is typically in a supervised setting 1. For outpatient tapering, the slower approach described above is generally safer and better tolerated 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.